Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...
Ronald J. Sokol, M.D., Pediatric Liver Center and Liver Transplantation Program and the Pediatric General Clinical Research Center, Department of Pediatrics, University of Colorado School of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback